Rhythm Pharmaceuticals, which is developing peptide-based therapies to treat rare genetic obesity, raised $120 million by offering 7 million shares at $17, above the range of $14 to $16. It originally filed to offer 6.7 million shares. Rhythm Pharmaceuticals plans to list on the Nasdaq under the symbol RYTM. Morgan Stanley, BofA Merrill Lynch and Cowen & Company acted as lead managers on the deal.
